During the corresponding time, Hutchmed China Limited saw a revenue deteriorated by -12.96 % year on year, While revenue at the Hutchmed China Limited's corporate clients
Hutchmed China Limited's Comment on Sales, Marketing and Customers
The company serves customers with appropriate credit history and conducts periodic credit evaluations. Its Oncology/Immunology operations focus on the commercialization of drug candidates savolitinib (marketed as Orpathys), fruquintinib (marketed as Elunate in China and Fruzaqla outside China), and surufatinib (marketed as Sulanda in China). Savolitinib is marketed in collaboration with AstraZeneca, fruquintinib with Eli Lilly and Takeda, while surufatinib is marketed independently. The company targets markets including the third-line metastatic colorectal cancer (mCRC) patient population in China. The success of commercialization depends on factors such as physician and patient acceptance and regulatory developments in China and globally.
In a notable advancement for the oncology and hematology communities, HUTCHMED (China) Limited has announced that it will unveil new and updated clinical data at two prominent international meetings the European Society for Medical Oncology (ESMO) Asia Congress 2025 and the American Society of Hematology (ASH) Annual Meeting. These presentations, scheduled to take place consecutively from December 5-9, 2025, in Singapore and Orlando, respectively, are poised to highlight HUTCHMED s commitment to advancing cancer therapeutics and hematological research through innovative compounds.The ESMO Asia Congress, a pivotal forum for oncologists across the Asia-Pacific region, will serve as the backdrop for the unveili...
HUTCHMED (China) Limited has announced the successful completion of patient enrollment for the SAFFRON trial, a significant global Phase III study investigating the combination of ORPATHYS (savolitinib) and TAGRISSO (osimertinib) in the treatment of non-small cell lung cancer (NSCLC). This trial is specifically designed for patients with epidermal growth factor receptor (EGFR) mutations and MET overexpression or amplification, particularly those who have experienced progression after treatment with TAGRISSO. The last patient was randomized on October 31, 2025, marking a crucial milestone in the study s timeline. Recent developments in oncological therapeutics have underscored a paradigm shift in the manag...
HUTCHMED Set to Showcase Innovative Lung Cancer Research at Major 2025 Conferences HONG KONG, SHANGHAI, and FLORHAM PARK, N.J., Sept. 5, 2025 HUTCHMED (China) Limited, a biopharmaceutical company dedicated to advancing innovative cancer treatments, has announced the presentation of new and updated clinical data concerning several of its proprietary compounds. These significant findings will be displayed at two prominent events in the global oncology calendar: the 2025 World Conference on Lung Cancer (WCLC) in Barcelona, Spain, from September 6-9, and the Chinese Society of Clinical Oncology (CSCO) Annual Meeting 2025 in Jinan, China, from September 10-14. A Commitment to Lung Cancer ResearchWith lung cance...
HUTCHMED (China) Limited, in collaboration with Innovent Biologics, Inc. has announced the acceptance of their New Drug Application (NDA) by the China National Medical Products Administration (NMPA) for the combination therapy involving fruquintinib and sintilimab. This therapy targets patients with locally advanced or metastatic renal cell carcinoma who have not responded to a prior tyrosine kinase inhibitor (TKI) treatment, illustrating a significant step forward in optimizing therapeutic strategies for this challenging oncological landscape. Background and Context Fruquintinib, developed by HUTCHMED, is a potent oral vascular endothelial growth factor receptor (VEGFR) inhibitor, designed to inhibit angiog...
HUTCHMED to Showcase Pioneering Clinical Data at 2024 Global Medical Conferences In an exciting advancement for oncology and hematology, HUTCHMED (China) Limited (Nasdaq/AIM: HCM; HKEX: 13) announced that new and updated data from its sovleplenib ESLIM-01 Phase III clinical trial will be presented at both the American Society of Hematology (ASH) Annual Meeting, from December 7-10, 2024, in San Diego, California, and the European Society for Medical Oncology (ESMO) Asia Congress, occurring from December 6-8, 2024, in Singapore. These presentations will further highlight HUTCHMED s dedication to advancing treatments in oncology and hematology through rigorous research and innovative clinical trials. Advancemen...
The forthcoming presentations will detail the efficacy and safety profiles of innovative compounds discovered by HUTCHMED. This includes drugs targeting various types of cancer, which hold potential to revolutionize current treatment paradigms. Given the stature of these international conferences, the data reveal will mark pivotal moments in the oncology community, further solidifying HUTCHMED’s role as a vanguard in cancer treatment development.
NDA Acceptance in China for Tazemetostat for the Treatment of Relapsed or Refractory Follicular Lymphoma with Priority Review Status'
Simultaneously, HUTCHMED has announced the acceptance of its New Drug Application (NDA) by the China National Medical Products Administration (NMPA) for tazemetostat, aimed at treating adult patients with relapsed or refractory follicular lymphoma (FL). The granting of Priority Review status underscores the therapeutic potential of tazemetostat, accelerating its path to market and promising expedited access for patients in dire need.
Follicular lymphoma, a subtype of non-Hodgkin lymphoma, often presents significant treatment challenges, particularly in relapsed or refractory stages. Tazemetostat’s acceptance for priority review in China signifies a hopeful milestone in expanding the treatment arsenal for this cancer, potentially offering a new lease on life for many patients.
Initiation of Phase I Trial of Menin Inhibitor HMPL-506 in Patients with Hematological Malignancies in China'
Adding to the wave of advancements, HUTCHMED has initiated a Phase I clinical trial of its new menin inhibitor, HMPL-506, in patients with hematological malignancies. The first patient received their dose on May 31, 2024. This development marks a vital step in exploring HMPL-506's efficacy and safety, paving the way for potential future treatments in blood cancers.
Menin inhibitors represent a novel approach in combating hematological malignancies by targeting the menin protein, which plays a critical role in certain cancer pathways. By initiating this trial, HUTCHMED continues to push the boundaries of innovative cancer treatment, showing its unwavering commitment to the advancement of oncology therapeutics.
Impact on HUTCHMED’s Trajectory'
HUTCHMED’s prolific string of achievements in clinical research and drug development is likely to bolster its standing in the biopharmaceutical industry significantly. Showcasing data at world-renowned conferences enhances its visibility and credibility among peers and stakeholders. The accelerated review process for tazemetostat in China could lead to faster commercialization and expanded market growth, while the initiation of a Phase I trial for HMPL-506 underscores its ongoing commitment to innovation in cancer therapy.
These advancements reflect not only the company’s robust RandD capabilities but also its strategic vision in addressing unmet medical needs across various cancer types. As these therapies progress through clinical stages and regulatory milestones, HUTCHMED stands to amplify its impact in the global oncology landscape, promising hope and improved outcomes for patients worldwide.
HUTCHMED Highlights Clinical Data to be Presented at ESMO Congress 2024 and the 2024 World Conference of Lung Cancer By WASHINGTON September 9, 2024 HUTCHMED (China) Limited, a global pharmaceutical giant specializing in the discovery, development, and commercialization of targeted therapies and immunotherapies for cancer and immunological diseases, is poised to reveal groundbreaking clinical data at several prestigious conferences this year. Notably, fresh findings from multiple studies of HUTCHMED’s novel compounds will be showcased at the 2024 World Conference on Lung Cancer (WCLC24) in San Diego, USA, and the European Society for Medical Oncology (ESMO) Congress 2024 in Barcelona, Spain.The forth...
HUTCHMED Presents Exciting Data on Sovleplenib Phase III Study and Hematological Malignancy Programs at EHA2024 CongressHONG KONG, SHANGHAI, and FLORHAM PARK, N.J., May 17, 2024 - HUTCHMED (China) Limited (HUTCHMED) (Nasdaq/AIM:HCM; HKEX:13) has announced its latest groundbreaking advancements in cancer research. The company will present the highly anticipated topline and subgroup results from the ESLIM-01 Phase III study of sovleplenib, along with new and updated data related to novel investigational hematological malignancy therapies HMPL-306, HMPL-760, and tazemetostat, at the upcoming European Hematology Association (EHA) Hybrid Congress. This prestigious event will take place on June 13-16, 2024, in Mad...
HUTCHMED, a leading biopharmaceutical company, has recently announced the initiation of the registration stage for the Phase II/III clinical trial of their drug sovleplenib. The trial aims to evaluate the efficacy and safety of sovleplenib in adult patients with warm antibody autoimmune hemolytic anemia (wAIHA) in China. This marks a significant milestone in HUTCHMED s efforts to address the unmet medical needs of patients suffering from this debilitating condition.wAIHA is a rare autoimmune disorder characterized by the destruction of red blood cells by autoantibodies. Currently, there are limited treatment options available for patients with wAIHA, highlighting the urgent need for innovative therapies. Sov...
HUTCHMED (China) Limited (HUTCHMED), a leading biopharmaceutical company, recently announced a strategic partnership with Inmagene Biopharmaceuticals (Inmagene), a renowned global player in the biopharmaceutical industry. As part of this partnership, Inmagene has exercised options to license two groundbreaking drug candidates discovered by HUTCHMED, namely IMG-007 and IMG-004. This momentous development marks a significant step forward in the advancement of innovative therapies, with Inmagene gaining exclusive rights to further develop, manufacture, and commercialize these two potential game-changers on a global scale.The strategic partnership between HUTCHMED and Inmagene, initially announced on January 11,...
HUTCHMED (China) Limited, a leading global biopharmaceutical company, is set to present new clinical data from ongoing studies at the upcoming European Society for Medical Oncology (ESMO) Asia Congress in Singapore and the ESMO Immuno-Oncology Congress in Geneva, Switzerland. The data will shed light on the potential of three investigational drug candidates - fruquintinib, surufatinib, and HMPL-295, developed by HUTCHMED. These crucial findings mark significant advancements in oncology research and hold promise for transforming treatment options for cancer patients worldwide. ESMO Asia Congress - December 1-3, 2023: HUTCHMED is excited to showcase the latest clinical data for fruquintinib, ...
Hutchmed China Limited’s Comment on Sales, Marketing and Customers
The company serves customers with appropriate credit history and conducts periodic credit evaluations. Its Oncology/Immunology operations focus on the commercialization of drug candidates savolitinib (marketed as Orpathys), fruquintinib (marketed as Elunate in China and Fruzaqla outside China), and surufatinib (marketed as Sulanda in China). Savolitinib is marketed in collaboration with AstraZeneca, fruquintinib with Eli Lilly and Takeda, while surufatinib is marketed independently. The company targets markets including the third-line metastatic colorectal cancer (mCRC) patient population in China. The success of commercialization depends on factors such as physician and patient acceptance and regulatory developments in China and globally.
Sources:
Hutchmed china Limited’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Hutchmed china Limited’s corporate clients.
For your research, we’ve provided 9 tables on Hutchmed china Limited corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
99.76 %